EP3592746A4 - Tyk2-inhibitoren, verwendungen und verfahren zu deren herstellung - Google Patents

Tyk2-inhibitoren, verwendungen und verfahren zu deren herstellung Download PDF

Info

Publication number
EP3592746A4
EP3592746A4 EP18764569.2A EP18764569A EP3592746A4 EP 3592746 A4 EP3592746 A4 EP 3592746A4 EP 18764569 A EP18764569 A EP 18764569A EP 3592746 A4 EP3592746 A4 EP 3592746A4
Authority
EP
European Patent Office
Prior art keywords
production
methods
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18764569.2A
Other languages
English (en)
French (fr)
Other versions
EP3592746B1 (de
EP3592746A1 (de
Inventor
Jeremy Robert Greenwood
Craig E. Masse
Jon P. Lawson
Jean-Baptiste ARLIN
David Pearson
Jonathan James LOUGHREY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Nimbus Lakshmi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Lakshmi Inc filed Critical Nimbus Lakshmi Inc
Priority to EP24153142.5A priority Critical patent/EP4338802A3/de
Publication of EP3592746A1 publication Critical patent/EP3592746A1/de
Publication of EP3592746A4 publication Critical patent/EP3592746A4/de
Application granted granted Critical
Publication of EP3592746B1 publication Critical patent/EP3592746B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP18764569.2A 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zu deren herstellung Active EP3592746B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24153142.5A EP4338802A3 (de) 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zur herstellung davon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468688P 2017-03-08 2017-03-08
PCT/US2018/021265 WO2018165240A1 (en) 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24153142.5A Division EP4338802A3 (de) 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zur herstellung davon

Publications (3)

Publication Number Publication Date
EP3592746A1 EP3592746A1 (de) 2020-01-15
EP3592746A4 true EP3592746A4 (de) 2020-11-25
EP3592746B1 EP3592746B1 (de) 2024-01-24

Family

ID=63446346

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24153142.5A Pending EP4338802A3 (de) 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zur herstellung davon
EP18764569.2A Active EP3592746B1 (de) 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zu deren herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24153142.5A Pending EP4338802A3 (de) 2017-03-08 2018-03-07 Tyk2-inhibitoren, verwendungen und verfahren zur herstellung davon

Country Status (10)

Country Link
US (2) US10336752B2 (de)
EP (2) EP4338802A3 (de)
JP (2) JP7160824B2 (de)
CN (1) CN110582501B (de)
AR (1) AR111233A1 (de)
AU (3) AU2018230737B2 (de)
CA (1) CA3055209A1 (de)
IL (1) IL269036B2 (de)
TW (2) TWI783978B (de)
WO (1) WO2018165240A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
JP2022502515A (ja) 2018-10-15 2022-01-11 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
SG11202104017VA (en) * 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
CN113677347A (zh) * 2019-02-07 2021-11-19 温缇克斯生物科学公司 Tyk2假激酶配体
KR20220004641A (ko) 2019-03-26 2022-01-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나아제 리간드
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
AU2020378345A1 (en) 2019-11-08 2022-06-02 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
IL311624A (en) * 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4983612A (en) * 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4343923A1 (de) * 1993-12-22 1995-06-29 Basf Ag Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DK1389617T3 (da) 2001-04-27 2007-05-07 Zenyaku Kogyo Kk Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2495072A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
AU2003291021A1 (en) * 2002-11-18 2004-06-15 The Regents Of The University Of California Arylpyridine compounds
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
KR101168441B1 (ko) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP2161275A1 (de) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs aus 2,4-Pyrimidindiamin-Verbindungen und ihre Verwendungen
WO2007040650A2 (en) 2005-05-12 2007-04-12 Abbott Laboratories Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
ES2513165T3 (es) 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060631A1 (es) 2006-04-26 2008-07-02 Piramed Ltd Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
EP2532235A1 (de) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Hemmer der Bruton-Tyrosinkinase
KR20150043565A (ko) 2007-03-12 2015-04-22 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP6157358B2 (ja) * 2010-12-22 2017-07-05 ルートヴィヒ‐マクシミリアン‐ユニバーシタット ミュンヘン 有機亜鉛錯体ならびに有機亜鉛錯体を作製および使用するための方法
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
DK3040336T3 (da) * 2012-03-02 2020-06-22 Sareum Ltd Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
CA2875990A1 (en) * 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
RS63328B1 (sr) 2012-11-08 2022-07-29 Bristol Myers Squibb Co Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AU2013341185B2 (en) 2012-11-08 2017-07-13 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
JP6458038B2 (ja) 2013-12-10 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
ES2921874T3 (es) * 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
US20160251376A1 (en) * 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
AU2017342464B2 (en) 2016-10-14 2021-09-16 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AR111233A1 (es) 2019-06-19
CN110582501B (zh) 2022-09-23
AU2024205575A1 (en) 2024-08-22
CN110582501A (zh) 2019-12-17
IL269036B2 (en) 2023-03-01
WO2018165240A1 (en) 2018-09-13
JP7535086B2 (ja) 2024-08-15
EP3592746B1 (de) 2024-01-24
US20190337941A1 (en) 2019-11-07
US20180258086A1 (en) 2018-09-13
JP7160824B2 (ja) 2022-10-25
JP2022185139A (ja) 2022-12-13
US11040967B2 (en) 2021-06-22
EP3592746A1 (de) 2020-01-15
IL269036A (en) 2019-10-31
IL269036B (en) 2022-11-01
AU2018230737B2 (en) 2022-09-22
AU2022256121A1 (en) 2022-11-17
JP2020511438A (ja) 2020-04-16
EP4338802A2 (de) 2024-03-20
TWI783978B (zh) 2022-11-21
TW201840559A (zh) 2018-11-16
TW202321243A (zh) 2023-06-01
CA3055209A1 (en) 2018-09-13
US10336752B2 (en) 2019-07-02
EP4338802A3 (de) 2024-09-04
AU2018230737A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
EP3592746A4 (de) Tyk2-inhibitoren, verwendungen und verfahren zu deren herstellung
EP3658557A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3526222A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3528816A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3344624B8 (de) Tyk2-inhibitoren und verwendungen davon
EP3596156A4 (de) Polyamide und verfahren zur herstellung davon
EP3262049A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3110820A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3655873A4 (de) Systeme und verfahren für blockchain-abhängige operationssätze
EP3408326A4 (de) Elastomere artikel, zusammensetzungen und verfahren zu deren herstellung
EP3509591A4 (de) Neuartige jak1-selektive inhibitoren und verwendungen davon
EP3448097A4 (de) Synchronisationsverfahren für endgerät sowie endgerät
EP3369734A4 (de) Kinaseinhibitor sowie herstellungsverfahren und pharmazeutische verwendung davon
EP3325608A4 (de) Verfahren und mikroorganismen zur herstellung von 1,3-butandiol
EP3594312A4 (de) Zusammensetzung, verfahren zur herstellung davon und verwendung davon
EP3309138A4 (de) Verfahren zur gemeinsamen erzeugung von 2,3,3,3-tetrafluorpropylen und 1,3,3,3-tetrafluorpropylen
EP3575853A4 (de) Verfahren zur herstellung einer stereoskopischen bilderzeugungsvorrichtung und stereoskopische bilderzeugungsvorrichtung
EP3485911A4 (de) Hartkapsel mit verbesserter härte und verfahren zur herstellung davon
EP3663324A4 (de) Blockcopolymer und verfahren zur herstellung eines blockcopolymers
EP3395366A4 (de) Wirkstoffdesignverfahren, erhaltener wirkstoff und anwendung davon
EP3693161A4 (de) Verfahren zur herstellung eines laminats und laminat
EP3483302A4 (de) Hartbeschichtung, werkzeug mit hartbeschichtung und verfahren zur herstellung beider
EP3676546A4 (de) Verfahren, systeme und vorrichtungen zur herstellung von feststoffen
EP3633713A4 (de) Verfahren zur herstellung einer struktur und struktur
EP3467043A4 (de) Wärmeleitendes element, wärmeleitende zusammensetzung und herstellungsverfahren für wärmeleitende zusammensetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20200710BHEP

Ipc: C07C 309/04 20060101ALI20200710BHEP

Ipc: A61K 31/437 20060101ALI20200710BHEP

Ipc: A61P 25/00 20060101ALI20200710BHEP

Ipc: A61P 37/00 20060101ALI20200710BHEP

Ipc: C07D 471/04 20060101AFI20200710BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017086

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018064510

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0491048000

Ipc: C07D0471040000

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0491048000

Ipc: C07D0471040000

A4 Supplementary search report drawn up and despatched

Effective date: 20201023

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20201019BHEP

Ipc: A61K 31/437 20060101ALI20201019BHEP

Ipc: C07C 309/04 20060101ALI20201019BHEP

Ipc: C07D 471/04 20060101AFI20201019BHEP

Ipc: A61P 35/00 20060101ALI20201019BHEP

Ipc: A61P 25/00 20060101ALI20201019BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220721

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20230630BHEP

Ipc: A61P 25/28 20060101ALI20230630BHEP

Ipc: A61P 25/00 20060101ALI20230630BHEP

Ipc: A61P 35/00 20060101ALI20230630BHEP

Ipc: A61K 31/437 20060101ALI20230630BHEP

Ipc: A61P 37/00 20060101ALI20230630BHEP

Ipc: C07C 309/04 20060101ALI20230630BHEP

Ipc: C07D 471/04 20060101AFI20230630BHEP

INTG Intention to grant announced

Effective date: 20230809

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018064510

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240220

Year of fee payment: 7

Ref country code: GB

Payment date: 20240220

Year of fee payment: 7

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240124

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240229

Year of fee payment: 7

Ref country code: FR

Payment date: 20240221

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240425

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1652133

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_35660/2024

Effective date: 20240613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240424

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240424

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240524

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240425

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240524

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240124